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1. Introduction 
1.1 Background 
Tuberculosis is the world’s second deadliest infectious disease, with nearly 9.3 million new 
cases diagnosed in 2007. According to the WHO, an estimated 1.8 million people died from 
TB in 2007. One-third of the world’s population is infected with the TB bacillus and current 
treatment takes 6–9 months. The current TB vaccine, Bacille Calmette-Guérin (BCG), 
developed almost 90 years ago, reduces the risk of severe forms of TB in early childhood but 
is not very effective in preventing pulmonary TB in adolescents and adults — the 
populations with the highest rates of TB disease. TB is changing and evolving, making new 
vaccines more crucial for controlling the pandemic. Tuberculosis is now the leading cause of 
death for people living with HIV/AIDS, particularly in Africa. Multidrug-resistant TB 
(MDR-TB) and extensively drug-resistant TB (XDR-TB) are hampering treatment and 
control efforts. New control measures, diagnostic tools and guidelines for treatment as well 
as development of new drugs and vaccines have been made a priority and the battle is now 
raging to restore the grip on the magement and control of MDR/XDR TB. Winning the 
battle against tuberculosis will depend on the outcomes of the extensive research that is on 
going to produce new, more effective and fast acting diagnostic tools, drugs and vaccines.  
1.2 Drug-resistant TB 
Drug-resistant TB is a result of mycobacterial strains that do not respond to drug treatment. 
Drug resistance has in the recent past become a serious global public health problem 
especially in the populations of the poor countries of the world. Multidrug-resistant 
tuberculosis (MDR-TB) refers to organisms that are resistant to at least two of the first-line 
drugs, isoniazid (INH) and rifampin, (RIF). In recent years, the world has seen a rapidly 
emerging epidemic of drug-resistant TB or multi drug-resistant (MDR-TB) and/or 
extensively drug-resistant XDR-TB ), which is highly lethal and extremely expensive leave 
alone being complicated to treat. Extensively drug-resistant tuberculosis (XDR-TB) is a type 
of multidrug-resistant tuberculosis (MDR-TB) that is resistant to two of the first-line drugs - 
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isoniazid and rifampicin - as well as to the second-line medications that include a 
fluoroquinolone such as ciprofloxacin and at least one of the injectable drugs which may be 
an aminoglycoside such as amikacin or kanamycin, or a polypeptide like capreomycin, or a 
thioamides such as ethionamide, or cycloserine or p-aminosalicylic acid. 
Because the treatment regimen for TB is long and complex, many patients are unable to 
complete the course of treatment, enabling their disease to develop drug-resistance. Once a 
drug-resistant strain has developed, it can be transmitted directly to others. XDR TB being 
resistant to the front-line drugs and two or more of the six classes of second-line drugs, this 
makes it virtually untreatable and HIV positive people are particularly at a greater risk. 
Therefore, XDR TB could have a bigger impact on developing nations considering the fact 
that there is high prevalence of HIV and lack of capacity to quickly and effectively diagnose 
and identify the disease. To prevent XDR-TB from spreading, there is an urgent need for 
new diagnostic tools and new and more effective anti TB drugs and vaccines to be 
developed. An estimated $5bn is required to confront the spread of DR TB. 
1.3 Inadequate treatment 
The current first-line TB drug regimen of four drugs is nearly 50 years old, takes six to nine 
months to complete and has significant side effects. Very often, these shortcomings cause 
patients to default on their treatment which, consequently, results in resistance to TB drugs 
which then spreads throughout the world. Treatment for MDR-TB or XDR-TB can last up to 
30 months, consists of many drugs, (including injectables), many of which have significant 
side effects, are extremely expensive and resource-intensive to deliver. With the rapid and 
lethal spread of drug-resistant TB, expediting the development of new, simpler and more 
effective drug regimens is now a major public health emergency. 
1.4 Nature of resistance 
In a study conducted by Ioerger et al.,(2009) titled “Genome Analysis of Multi- and 
Extensively-Drug-Resistant Tuberculosis from KwaZulu-Natal, South Africa”, which was 
designed to investigate the causes and evolution of drug-resistance, it was observed that 
polymorphisms among the strains was consistent with the drug-susceptibility profiles, in 
that well-known mutations correlated with resistance to isoniazid, rifampicin, kanamycin, 
ofloxacin, ethambutol, and pyrazinamide. It was however, realised that the mutations 
responsible for rifampicin resistance in rpoB and pyrazinamide in pncA are in different 
nucleotide positions in the multi-drug-resistant and extensively drug-resistant strains, 
which was taken to be an indication that they acquired these mutations independently, and 
that the XDR strain could not have evolved directly from the MDR strain though it could 
have arisen from another similar MDR strain.  
The researchers reported that the MDR and XDR strains contain typical mutations in gyrA, 
rpoB, rrs, katG, and the promoter of inhA that explain resistance to fluroquinalones, 
rifampicin, kanamycin, and isoniazid. Although susceptibilities to ethambutol and 
pyrazinamide were not determined clinically, mutations in embB and pncA were observed 
as well. They further argued that the fact that the MDR and XDR strains have different 
mutations in rpoB and pncA suggests that they arose separately, and that these mutations 
were acquired independently after divergence. This observation contradicts the hypothesis 
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that the XDR strain might have evolved directly from the MDR strain (though it could have 
arisen from another similar MDR strain). While resistance to streptomycin is usually 
associated with mutations in rpsL or rrs, the KZN MDR and XDR strains showed a rare 130 
bp deletion in gidB. Although recent studies have begun to show that mutations can cause 
low-level resistance to streptomycin, through abbrogation of ribosomal methylation, this 
mutation was unique and had never been reported before. 
Consistent with what was already known, the researchers found that only the XDR strain 
KZN-R506 showed a mutation in rrs, the 16S rRNA, at position 1400, which explains the 
kanamycin resistance as put forward by Suzuki et al., (1998) and that only the XDR strain 
had the A90V mutation in gyrA responsible for resistance to fluoroquinolones as presented 
by Aubry et al., (2006). They further reported that the mutation at 1400 in rrs which is the 
most commonly observed mutation associated with kanamycin resistance, found in 60% of 
rifampicin-resistant clinical isolates was consitent with findings of Suzuki et al., (1998). The 
A90V in gyrA, the second-most frequently observed mutation conferring fluoroquinolone 
resistance, found in 24% of fluoroquinolone-resistant clinical isolates, is also reported to 
show agreement with the work of van Doorn et al.,(2008) on fluoroquinolone resistance. 
With respect to isoniazid (INH) resistance, it is also reported that both strains have the 
mutation of S315T in katG, the catalase/peroxidase that activates the pro-drug isoniazid as 
reported by Zang et al.,(1992). The finding that this is the most frequently observed 
mutation associated with isoniazid resistance was also consistent with the report by Hazbón 
et al.,(2006) and Pym et al.,(2002). The role of the c-15t inhA promoter mutation, and 
mutations in katG in ETH/INH co-resistance is also presented as put forward by Morlock et 
al., (2006)  
Resistance to rifampicin (RIF) can be explained by mutations in rpoB (beta-subunit of RNA 
polymerase). The mutation of Asp 435 in rpoB, was observed to confer rifampicin-resistance 
as put forward by Ramaswamy and Musser (1998). Ioerger et al.,(2009) further report that 
this is in the core 507–533 region, in which numerous mutations have been observed to 
cause resistance to RIF, although they agree that mutations at other sites in this region are 
more frequent. However, they report that the two Kwazulu Natal strains have different 
mutations within the same codon, leading to different amino acid substitutions. Strain KZN-
V2475 was found to have a G->T substitution in frame 1, producing D435Y, and KZN-R506 
with an A->G substitution in frame 2, producing D435G, a case that led the researchers to 
suggest that the two strains acquired rifampicin resistance independently. They also noted 
that the XDR strain, KZN-R506, contains two additional mutations in rpoB, L452P and 
I1106T; the former also being thought to cause RIF-resistance, while the latter does not. 
Ioerger et al.,(2009) further contend that streptomycin (STR) resistance is most likely due to 
a 130 bp deletion in gidB found in both MDR and XDR strains, but not the wild-type. The 
classic STR-R mutations that have been correlated with streptomycin-resistance in the 530-
loop or 915-region of rrs, the 16S ribosomal RNA, or in rpsL, the ribosomal protein S12, were 
not observed in either strain. However, they also state that mutations in these two genes 
explain only about 70% cases of STR resistance in clinical isolates (Sreevatsan et al., 1997) 
implying that there must be other loci that can be responsible. They further add that, despite 
the mutations in gidB having previously been observed in clinical isolates of M. tuberculosis 
by Nishimura et al., (2007) that, this 130 bp deletion is distinct from every other gidB 
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mutation previously reported. They report that the 130 bp gidB deletion observed in the 
KZN MDR and XDR strains spans amino acids 50–93, which encompasses the SAM-binding 
site (Romanowski et al., 2002) and causes a frame shift for C-terminal remainder, which is 
presumed to abbrogate function completely. They report that both strains also show classic 
mutations in embB, pncA, and the promoter region of ethA, which are associated with 
resistance to ethambutol (EMB), pyrazinamide (PZA), and ethionamide (ETH), though 
susceptibility to these drugs was not tested. It is further reported that the M306V mutation 
in the transmembrane protein embB is one of the most frequently observed mutations in 
EMB-resistant strains as reported by Sreevatsan et al.,(1997) and that this mutation 
putatively prevents ethambutol from interfering with biosynthesis of the arabinogalactan 
layer in the cell wall. In the case of pncA, they further report that the two drug-resistant 
KZN strains showed different mutations in pncA, a pyrazinamidase, which is thought to be 
involved in nicotinamide biosynthesis. They futher report that the MDR strain KZN-V2475 
has a G132A mutation, and that mutations of this residue have previously been reported to 
cause resistance to PZA Sreevatsan et al.,(1997). They further report that strain KZN-R506 
has a frame-shift mutation in amino acid 152 caused by an insertion of 1 bp, and missense 
mutations that cause resistance that have been observed downstream of this site and that 
they believe that the C-terminus of the 186-residue gene product must be important. They 
add that the two drug-resistant strains also share a mutation at position −8 upstream of the 
translational start site of ethA, which is a monooxygenase that activates thioamides such as 
ethionamide, isoxyl, and thioacetazone as pro-drugs as reported by Dover et al.,(2007). The 
researchers further contend that a mutation in the upstream region could potentially confer 
resistance by increasing expression although susceptibility of the KZN strains to these drugs 
was not determined 
It is further reported by the study that the MDR and XDR strains contain typical mutations 
in gyrA, rpoB, rrs, katG, and the promoter of inhA that explain resistance to 
fluroquinalones, rifampicin, kanamycin, and isoniazid. Mutations in embB and pncA were 
also observed. It is further argued that the fact that the MDR and XDR strains have different 
mutations in rpoB and pncA which suggests that they arose separately, and that these 
mutations were acquired independently after divergence. The researchers further report 
that, the Kwazulu Natal MDR and XDR strains studied showed a rare 130 bp deletion in 
gidB although resistance to streptomycin is usually associated with mutations in rpsL or rrs. 
The researchers coclude by recommending further analysis and comparison of the genome 
sequences they have reported in order to bring out a better understanding of the nature of 
the virulence XDR-TB strains. 
1.5 Epidemiology of drug-resistant TB 
In South Africa, an epidemic of XDR-TB was reported in 2006 as a cluster of 53 patients in a 
rural hospital in KwaZulu-Natal of whom 52 died - Tugela Ferry case. What was 
particularly worrying was that the mean survival from sputum specimen collection to death 
was only 16 days and that the majority of patients had never previously received treatment 
for tuberculosis. This was the epidemic for which the acronym XDR-TB was first used, 
although TB strains that fulfil the current definition have been identified since then, though 
retrospectively. This was the largest group of linked cases ever found; after the initial report 
in September 2006, cases have now been reported in most provinces in South Africa, the 
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neghbouring countries and the world at large, with more than 50 countries on all the 
inhabited continents having reported XDR-TB cases.  
MDR/XDR-TB can develop in the course of the treatment of fully sensitive TB and this is 
always the result of patients missing doses or failing to complete a course of treatment. 
Although there are reports that these resistant strains appear to be less fit and less 
transmissible, the high mortality rate especially where there is co-infection with HIV or 
during use of immunosuppressive drugs, this warrants that the epidemic has to be taken 
seriously. There is strong evidence that the spread of XDR-TB strains is very much 
associated with a high prevalence of HIV and poor infection control, and in some 
countries the upsurge of XDR-TB has been attributed to mismanagement of cases or poor 
patient compliance with drug treatment. 
XDR-TB does not respond to any of the drugs currently available in most developing 
countries for first- or second-line treatment. Considering the fact the problem is wide spread 
globally, strict isolation procedures have been suggested to mitigate rapid spread of XDR-
TB. The World Health Organization (WHO) recommends improving basic TB care to 
prevent emergence of resistance, the development of proper laboratories for detection of 
resistant cases, and when drug-resistant cases are found, it recommended prompt and 
appropriate treatment to prevent further transmission.  
Collaborative care for both HIV and TB is also recommended to help limit the spread of 
tuberculosis, both sensitive and resistant strains. The spread of drug-resistant cases has also 
been linked to overcrowding in places such as seen in prison populations, although the 
major reason for the development of resistance is poorly managed TB care which may be in 
form of poor patient compliance, inappropriate dosing or prescribing of medication, poorly 
formulated medications, and/or an inadequate supply of medication.  
1.6 Challenges presented by MDR/XDR TB 
First, research has revealed that drug-susceptible (regular) TB and MDR/XDR TB are 
transmitted in the same way. Transmission of XDR TB is in clusters and follows similar 
transmission patterns as ordinary TB. This makes it difficult to put appropriate barriers to 
the transmission of the deadly strains. To make matters worse, proper diagnosis involving 
culture and sensitivity tests is the most commonly used diagnostic method especially in the 
poor countries. This may take from 6 to 16 weeks, before XDR TB is confirmed during which 
time it is likely to have spread to other patients and possibly health workers. There have 
been no new diagnostic tests invented for many years and therefore most laboratories in 
these areas have limited capacity to respond to XDR-TB. Most laboratories, especially those 
in developing countries lack the facilities and guidelines for the use of conventional and 
rapid culture-based or molecular methods for detection of M. tuberculosis and drug 
resistance and this impedes the widespread use of these tests. The laboratory confirmation 
of TB in HIV-infected persons is even more difficult and time consuming and highly 
sensitive and sophisticated and requires technically challenging diagnostic tests that are not 
universally available in all settings with a high burden of HIV and TB. There is, therefore, 
poor surveillance especially in the poor developing countries and this presents serious 
difficulties in identifying and locating the XDR TB cases. A further complication is that TB 
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affects mostly poor people who live in places where health care is not easily accessible and 
where the patients have to pay for their own transportation 
The next challenge is that there are limited treatment options for XDR-TB especially in the 
developing countries and this makes the disease virtually untreatable. Considering the fact 
the majority of patients infected with XDR-TB are co infected with HIV/AIDS and that co-
infection has been found to be virtually 100% fatal, this makes the situation more serious. In 
spite of this serious threat, the world is not responding fast enough and with enough 
resources as was the case with SARS, avian flu or swine flu. Stop TB estimates that through 
2015, it will take about $2.4 billion for further discovery and early-stage development work 
and another $2.4 billion for clinical trials for new anti TB drugs. Considering the fact that the 
currently available resources are believed to total about $600 million, this leaves a 
substantial funding gap. More funding has to be directed towards research and 
development of new TB drugs and vaccines if the pandemic is to be defeated effectively. 
With regard to anti-tuberculosis drugs and vaccines, the world’s only vaccine (BCG) is 
almost 100 years old and only effective in children and for over 40 years there has been no 
new TB drug put on the market. This may be attributed to the high rates of failures of new 
drugs at clinical trials but it could also partly be due to complacency that tuberculosis was a 
defeated disease whose prevalence was on the decline especially in the USA. Another 
handicap has been that clinical trials required to register a TB drug can take a minimum of  
6 years, much longer than trials for other infectious diseases.  
A further complication is from drug-drug interactions in patients with TB/HIV co-infection. 
This is a serious hindering factor in finding treatments for people co-infected with TB and 
HIV. For example it is reported that rifampicin, which inhibits RNA polymerase, interacts 
with cytochrome P450 isozyme and causes some HIV drugs to be cleared quickly. To make 
matters worse clinicians, laboratory technologists, health-care professionals, public health 
officials, and policy makers do not possess up-to-date knowledge of what constitutes 
appropriate laboratory capabilities and capacities. 
2. The global MDR/XDR response plan 2007-2008 
Objectives for the Response were the following: (1) Strengthen basic activities to control TB 
and HIV/AIDS, as detailed in the Stop TB Strategy; (2) Scale-up the programmatic 
management of MDR-TB and XDR-TB to reach the targets set forth in the Global Plan; 
(3)Strengthen laboratory services for adequate and timely diagnosis of MDR- TB and XDR-
TB; (4) Expand surveillance of MDR-TB and XDR-TB to better understand the magnitude 
and trends of drug resistance and the links with HIV; (5) Foster sound infection control 
measures to avoid MDR-TB and XDR-TB transmission to protect patients, health workers, 
others working in congregate settings, and the broader community, especially in high HIV 
prevalence settings; (6) Strengthen advocacy, communication and social mobilization for 
sustained political commitment and a patient centred approach to treatment; (7) Pursue 
resource mobilization at global, regional and country levels to ensure that necessary 
resources are available; and (8) Promote research and development into new diagnostics, 
drugs, vaccines, and operational research on MDR-TB management to shorten treatment. 
(Adopted from: WHO Report,2007) 
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3. Treatment of MDR/XDR -TB 
3.1 Monitoring DOTS-plus 
The WHO extended the DOTS programme in 1998 to include the treatment of MDR-TB 
(called "DOTS-Plus"). Implementation of DOTS-Plus requires the capacity to perform drug-
susceptibility testing and the availability of second-line agents, in addition to all the 
requirements for DOTS. DOTS-Plus is therefore much more resource intensive than DOTS, 
and requires much greater commitment from countries wishing to implement it. Resource 
limitations mean that the implementation of DOTS-Plus may lead inadvertently to the 
diversion of resources from existing DOTS programmes and a consequent decrease in the 
overall standard of care (Dauby et al., 2011;Tam et al.,2009; Li et al., 2006).  
Monthly surveillance until cultures convert to negative is recommended for DOTS-Plus, but 
not for DOTS. If cultures are positive or symptoms do not resolve after three months of 
treatment, it is necessary to re-evaluate the patient for drug-resistant disease or non-
adherence to drug regimen. If cultures do not convert to negative despite three months of 
therapy, some physicians may consider admitting the patient to hospital so as to closely 
monitor therapy. 
3.2 Management of TB/HIV co-infection 
In patients with HIV, treatment for the HIV should be delayed until TB treatment is 
completed, if possible. The current UK guidance, provided by the British HIV Association, is 
that for a CD4 count over 200, treatment should be delayed until the six months of TB 
treatment are complete; for a CD4 count of 100 to 200, treatment should be delayed until the 
initial two-month intensive phase of therapy is complete ; while for a CD4 count less than 
100, the situation is unclear and they recommend clinical trials to examine the issue. There is 
need for patients in this category to be managed by a specialist in both TB and HIV so that 
they are not compromised for either disease.  
If HIV treatment has to be started while a patient is still on TB treatment, it is recommended 
that the advice of an HIV specialist should be sought. In general, reports say that there is no 
significant interactions with the NRTI's. Nevirapine should not be used with rifampicin. 
Efavirenz may be used, but the dose used depends on the patient's weight (600 mg daily if 
weight less than 50 kg; 800 mg daily if weight greater than 50 kg). Efavirenz levels should be 
checked early after starting treatment. The protease inhibitors should be avoided if at all 
possible because patients on rifamycins and potease inhibitors have an increased risk of 
treatment failure or relapse. The WHO also warns against using thioacetazone in patients 
with HIV, because of the 23% risk of potentially fatal exfoliative dermatitis.  
3.3 Specific treatment of MDR-TB 
The treatment and prognosis of MDR-TB are much more akin to that for cancer than to that 
for infection. It has a mortality rate of up to 80%, which depends on a number of factors, 
including: (1) How many drugs the organism is resistant to (the fewer the better); (2) How 
many drugs the patient is given (patients treated with five or more drugs do better); (3) 
Whether an injectable drug is given or not (it should be given for the first three months at 
least); (4) The expertise and experience of the physician responsible; (5) How co-operative 
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the patient is with treatment (treatment is arduous and long, and requires persistence and 
determination on the part of the patient) ; and (6) Whether the patient is HIV positive or not 
(HIV co-infection is associated with an increased mortality). 
Treatment courses take a minimum of 18 months and may last for years; it may require 
surgery, though death rates remain high despite optimal treatment. That said, good 
outcomes are still possible. Treatment courses that are at least 18 months long and which 
have a directly observed component can increase cure rates to 69%. 
Treatment of MDR-TB must be done on the basis of sensitivity testing since it is impossible 
to treat such patients without this information. When treating a patient with suspected 
MDR-TB, the patient should be started on streptomycin, isoniazid, rifampicin, ethambutol, 
pyrazinamide + moxifloxacin + cycloserine (SHREZ+MXF+cycloserine) pending the result 
of laboratory sensitivity testing. A gene probe for rpoB is available in some countries and 
this serves as a useful marker for MDR-TB, because isolated RMP resistance is rare, except 
when patients have a history of being treated with rifampicin alone. If the results of a gene 
probe (rpoB) are known to be positive, then it is reasonable to omit RMP and to use 
SHEZ+MXF+cycloserine. The reason for maintaining the patient on INH despite the 
suspicion of MDR-TB is that INH is so potent in treating TB that it would be irrational to 
omit it until there is microbiological proof that it is ineffective. There are also probes 
available for isoniazid-resistance (katG and mabA-inhA), but these are less widely available. 
When sensitivities are known and the isolate is confirmed as resistant to both INH and 
RMP, five drugs should be chosen in the following order (based on known sensitivities):  
(1) an aminoglycoside such as amikacin, kanamycin or a polypeptide antibiotic such as 
capreomycin; (2) pyrazinamide; (3) ethambutol; (4) a fluoroquinolones (moxifloxacin is 
preferred and ciprofloxacin should no longer be used]); (5) rifabutin; (6) cycloserine;  
(7) a thioamide: prothionamide or ethionamide; (8) PAS; (9) a macrolide such as 
clarithromycin; (10) linezolid; (11) high-dose INH (if low-level resistance); (12) interferon-γ; 
(13) thioridazine; and (14) meropenem and clavulanic acid. Drugs near the top of the list are 
more effective and less toxic while drugs placed near the bottom of the list are less effective 
or more toxic, or more difficult to obtain. 
Resistance to one drug within a class generally means resistance to all drugs within that 
class, but a notable exception is rifabutin for which rifampicin-resistance does not always 
mean rifabutin-resistance and the laboratory should be asked to test for it. It is only possible 
to use one drug within each drug class and if it is difficult to find five drugs to use then the 
clinician can request that high level INH-resistance be looked for. If the strain has only low 
level INH-resistance (resistance at 1.0 µg/ml INH, but sensitive at 0.2 µg/ml INH), then 
high dose INH can be used as part of the regimen.  
When counting drugs, PZA and interferon are counted as zero i.e. when adding PZA to a 
four drug regimen, you must still choose another drug to make five. It is not possible to use 
more than one injectable (capreomycin or amikacin), because the toxic effect of these drugs 
is additive: if possible, an aminoglycoside should be given daily for a minimum of three 
months (and perhaps thrice weekly thereafter). Ciprofloxacin should not be used in the 
treatment of tuberculosis if other fluoroquinolones are available. 
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There is no intermittent regimen validated for use in MDR-TB, but clinical experience is that 
giving injectable drugs for five days a week (because there is no-one available to give the 
drug at weekends) does not seem to result in inferior results. DOTS Plus strategy has been 
found to help in improving outcomes in MDR-TB and it is recommended that it should be 
an integral part of the treatment of MDR-TB. 
Response to treatment must be obtained by repeated sputum cultures (monthly if possible). 
Treatment for MDR-TB must be given for a minimum of 18 months and cannot be stopped 
until the patient has been culture-negative for a minimum of nine months. It is not unusual 
for patients with MDR-TB to be on treatment for two years or more. 
To be able to contain the spread of resistance, patients with MDR-TB should be isolated in 
negative-pressure rooms, if possible. Patients with MDR-TB should not be accommodated 
on the same ward as immunosuppressed patients (HIV-infected patients, or patients on 
immunosuppressive drugs). Careful monitoring of compliance with treatment is crucial to 
the management of MDR-TB and hospitalisation should be encouraged for this reason. If 
possible these patients should be isolated until their sputum is smear negative, or even 
culture negative, a process that may take many months, or even years. Since keeping these 
patients in hospital for long periods may not be practicablel, the final decision depends on 
the clinical judgement of the physician treating that patient. In addition, the attending 
physician should make full use of therapeutic drug monitoring (particularly of the 
aminoglycosides) both to monitor compliance and to avoid toxic effects. 
Some supplements may be useful as adjuncts in the treatment of tuberculosis, but for the 
purposes of counting drugs for MDR-TB, they count as zero (if you already have four drugs 
in the regimen, it may be beneficial to add arginine or vitamin D or both, but you still need 
another drug to make five). The supplements include arginine (peanuts are reported to be a 
good source) and Vitamin D. 
There are also some drugs which have been used in desperation and for which it is 
uncertain whether they are effective at all or not, but which are used when it is not possible 
to find five drugs from the list above. They include imipenem, co-amoxiclav, clofazimine, 
prochlorperazine and metronidazole. 
There is also increasing evidence for the role of surgery (lobectomy or pneumonectomy) in 
the treatment of MDR-TB, although whether this is should be performed early or late is not 
yet clearly defined (Mohsen et al, 2007). 
3.4 Specific treatment for XDR-TB 
Can XDR TB be treated and cured? Yes, in some cases. Some TB control programs have 
shown that aggressive treatment, using the current drug regimens can make it possible to 
effect cure for an estimated 30% of affected people. Researchers have shown that a cure is 
possible with a combination of at least five drugs as is the case with MDR-TB. Tailored 
treatment in 600 patients in Russia with at least five drugs showed that almost half of XDR-
TB patients had treatment cure on completion of the course. The study reported that 
aggressive management of the disease is feasible and can prevent high mortality rates and 
further transmission of drug-resistant strains of TB. However, the treatment is extremely 
labour and resource intensive and has to be done within extremely well structured TB 
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programmes. It is further reported that successful outcomes depend greatly on the extent of 
the drug resistance, the severity of the disease, whether the patient’s immune system is 
weakened, and adherence to treatment. There are no newly approved drugs or vaccines 
specifically for the treatment of XDR-TB although a number of drugs and vaccines are 
reported to be in various stages of development (Dauby et al., 2011). 
3.5 New drugs in the pipeline 
There is a desperate need for new and better TB treatments to address today’s growing 
pandemic, which kills nearly 2 million people each year. There have been no new TB drugs 
for nearly 50 years and, until the past decade, there was no pipeline of TB drug candidates. 
Now, with increased investments in TB R&D, there are 9 promising TB compounds in the 
pipeline from six antibiotic classes, making combination testing of new TB drugs possible. 
The eperimental drugs PA-824 (manufactured by PathoGenesis Corporation, Seattle, 
Washington), and R207910 (under development by Johnson & Johnson) are experimental 
compounds that are not commercially available, but which may be available from the 
manufacturer as part of a clinical trial or on a compassionate basis because their efficacy and 
safety are not yet properly understood. There are also reports that a Ukrainian herbal 
product which has been the subject of several small, open label clinical trials in TB patients 
and in patients with TB/HIV coinfection has produced promising results. Furthermore, 
Open Label trials with Dzherelo/Immunoxel have been reported to produce positive results 
in MDR and XDR-TB patients. 
Stirling Products Ltd of Australia has also announced further work on drug-resistant TB and 
TB/HIV with trials being carried out in Nigeria. V-5 Immunitor (known as "V5"), an oral 
hepatitis B and hepatitis C treatment vaccine and administered as simple tablets is being 
developed for patients co-infected with hepatitis C and tuberculosis. It is reported to 
produce TB sputum clearance within only one month. Further blinded studies at multiple 
trial centres have reported that V5 is equally effective against multiple drug resistant 
tuberculosis (MDR-TB). 
Currently, about 30 compounds have been identified for potential development of new anti 
TB drugs. However, new treatment for XDR TB is expected to be available not earlier than 
2012. Drugs in the pipeline include, among others, combination regimens containing the 
fluoroquinolones moxifloxacin and gatfloxacin. Moxifloxacin (from Bayer and TB Alliance) 
is being looked at as a substitute for isoniazid or ethambutol and should now be undergoing 
final clinical trials while gatfloxacin (from OFLOTUB) is being developed to replace 
ethambutol. Other drugs in the pipeline include LL3858 (from Lopin) which should have by 
now gone through Phase I clinical trials.Work also continues on rifabutin (related to 
rifampicin) (from Pfizer) which is under study to replace rifampicin and on rifapentine, 
which was approved in 1998. 
PA-824, a nitroimidazole, (from Chiron –part of Norvatis) is under Phase II Clinical trials 
while OPC-67683, a nitrodihydroimidazo-oxazole derivative (from Japan’s Otsuk 
Pharmaceuticals) is in advanced stages of clinical trials for treatment of MDR TB. TMC-207 
(from Johnson & Johnson), an ATP synthase inhibitor that is selective for MTB is under 
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development at Tibotec for MDR TB and is being considered as substitute for rifampicin and 
isoniazid to shorten the dosage period for MDR TB. 
FAS20013, a sulfonyl tridecamide (from FASgen) is also being developed against MDR TB. It 
interferes with MTB cell wall synthesis and is expected to be effective against dormant 
bacteria. 
SQ109, a 1, 2-ethylene diamine (from Sequella) is reported to inhibit cell wall synthesis and 
to have shown synergistic effect with rifampicin and isoniazid. It is also reported to be 
effective against MDR and latent forms. SQ609, a dipiperidine (from Sequella but got from 
Sankyo, Japan), which is an inhibitor of translocase, involved in cell wall synthesis, is in pre-
clinical studies. 
Source: U.S. National Institute of Allergy and Infectious Diseases (NIAID) 
3.6 Ongoing research: New paradigm shift 
Treating active TB requires a combination of drugs to prevent the development of drug 
resistance. Traditionally, researchers tested one new drug at a time in a series of lengthy and 
expensive clinical trials, meaning it would take decades to develop a completely novel drug 
combination. The individual TB drug candidates were developed and registered separately, 
by being substituted (or added) one at a time to the existing standard, four-drug- 
combination TB therapy. Because each substitution (or addition) could take six years or 
longer, the approval of a new four-drug TB regimen, through successive trials, could take 
nearly a quarter of a century to develop under this framework. With nearly 2 million people 
dying of TB each year, the world cannot wait that long for the tools needed to stop this 
devastating disease.  
The push in this direction is because there is a possibility of developing one TB drug 
regimen capable of treating both drug-sensitive and multidrug- and extensively drug-
resistant tuberculosis using combination therapy. Combination drug regimen may 
especially transform MDR/XDR-TB treatment, resulting in reduction of treatment 
duration from 2 years to less than six months. This new approach to drug development is 
expected to expedite the development and production of regimens that can be availed to 
patients in a much smaller period of time compared to the traditional approach of drug 
development. 
This research approach is being championed by the Critical Path to TB Drug Regimens 
(CPTR), an initiative established to tackle the regulatory and other challenges associated 
with TB drug development. CPTR was founded in March 2010 by the Bill & Melinda Gates 
Foundation, the Critical Path Institute, and the TB Alliance. CPTR focuses on shifting the 
unit of development from an individual drug to combinations of drugs, which can be tested 
together and developed as a regimen from early clinical testing. Advances in regulatory 
science will help clearly evaluate experimental TB drugs both on their own and within the 
context of a regimen.  
This new approach has the potential to shorten the time needed to develop new TB 
treatment regimens by decades, as well as significantly reduce development costs. However, 
to be able to test promising combinations together, there must be a change in today’s 
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thinking about TB research— a paradigm shift - and the change must be adopted by 
everyone: drug sponsors, global regulators, WHO, patients, and other stakeholders 
throughout the TB landscape. This new approach to drug development enables 
combinations of previously unregistered TB drugs to be tested together, with the goal of 
introducing truly innovative regimens in only a fraction of that time. Nearly a dozen 
pharmaceutical companies, civil society organizations, the European and Developing 
Countries Clinical Trials Partnership (EDCTP), and others have signed on to the initiative’s 
guiding principles. The US Food and Drug Administration, other regulatory bodies, and the 
World Health Organization have all shown support for this initiative. 
In persuit of this paradigm shift, the 41st Union World Conference, the Global Alliance for 
TB Drug Development (TB Alliance) in Berlin, Germany on Nov. 8, 2010 announced the 
launch of the first clinical trial to test a novel tuberculosis regimen designed to expedite new 
treatments to patients. The novel three-drug combination has shown promising results 
towards treating both drug-sensitive (DS-TB) and multidrug-resistant TB (MDR-TB), and 
also being able to alter the course of the TB pandemic by shortening and simplifying 
treatment worldwide. 
The combination now in Phase III clinical trials is called NC001 or New Combination 1. The 
new combination TB drug candidate being tested contains PA-824 and moxifloxacin in 
combination with pyrazinamide, an existing antibiotic commonly used in TB treatment 
today. The developers have reported that preclinical data have revealed that the 
combination has potential to shorten treatment time for virtually all tuberculosis patients 
and to harmonize the treatment of drug susceptible tuberculosis (DS-TB) and MDR-TB and 
possibly XDR-TB treatment with a single three-drug regimen. This is a particularly 
significant advance for MDR-TB patients, who today must take multiple types of drugs, 
including injectables, daily for up to two years. It is envisaged that, if successful, the 
experimental regimen will offer a shorter, simpler, safer, and more affordable treatment 
option for MDR-TB, an emerging global health threat. The new compounds are being 
developed by TB Alliance, but with moxifloxacin being developed in partnership with Bayer 
HealthCare AG.  
The trial involves 68 participants at two centers in South Africa, each receiving two weeks of 
treatment and three months of follow-up to evaluate effectiveness, safety, and tolerability. 
NC001 is an early bactericidal activity trial and is supported financially by United States 
Agency for International Development, the Bill & Melinda Gates Foundation, and the 
United Kingdom’s Department for International Development. 
NC001, is also testing additional two-drug combinations (TMC207/pyrazinamide and PA-
824/pyrazinamide) that may prove to be the building blocks of future regimens. Regimen 
development may become the new gold standard in TB research and offer lessons for other 
diseases requiring combination treatment, such as cancer, hepatitis C, and malaria. 
However, there remains a vital need for funding to bring new TB regimens through late-
stage clinical trials. 
Table 1 gives a summary of the various compounds and combinations that are in various 
stages of development. 
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 Discovery Pre-clinical 
Development 
 Clinical Development 
Target or  
cell-based 
screening 
Lead 
identification
Lead 
optimization 
 Clinical 
Phase I 
 Clinical phase II Clinical 
phase III 
Natural 
Products 
IMCAS 
Whole-Cell 
Hit to Lead 
Program  
GSK 
Mycobacterial 
Gyrase 
Inhibitors GSK
Nitroimidazoles 
U. of Auckland/ 
U. Ill Chicago 
 PA-824  
Novartis 
(NTBRD) 
Moxiflox
acin  
(+H, R, Z)  
Bayer 
TB Drug 
Discovery 
Portfolio  
NITD 
 Pyrazinamide 
Analogs 
Yonsei 
Preclinical TB 
Regimen 
Development 
JHU/U. Ill 
Chicago 
(NTBRD) 
 Preclinical TB 
Regimen 
Development 
JHU/U. Ill 
Chicago 
(NTBRD) 
Moxiflox
acin  
(+R, Z, E)  
Bayer 
Topoisomerase 
I Inhibitors 
AZ/NYMC 
Gyrase B 
Inhibitors 
AZ 
Diarylqu-
inolines  
Tibotec/U. of 
Auckland 
   PA-
824/Pyrazinamide 
(NTBRD) 
 
 Folate 
Biosynthesis 
Inhibitors 
AZ 
Rimino-
phenazines 
IMM/BTTTRI 
  TMC207/Pyrazina
mide 
(NTBRD) 
 
 
 
Whole-Cell 
Hit to Lead 
Program AZ
   PA-824/TMC207 
(NTBRD) 
 
 
 
 RNA 
Polymerase 
Inhibitors  
AZ 
    PA-824/ 
Moxifloxacin/  
Pyrazinamide 
(NTBRD) 
 
 
 
 Energy 
Metabolism 
Inhibitors 
AZ/U. Penn
 
     
Key: AZ = AstraZeneca, Bayer = Bayer Healthcare AG, BTTTRI = Beijing Tuberculosis and Thoracic, 
Tumor Research Institute, GSK = GlaxoSmithKline, IMM = Institute of Materia Medica, IMCAS = 
Institute of Microbiology, Chinese Academy of Sciences, JHU = Johns Hopkins University, Tibotec = 
Johnson & Johnson / Tibotec, NYMC = New York Medical College, NITD = Novartis Institute for 
Tropical Diseases, Novartis = Novartis Pharmaceutical, U. of Auckland = University of Auckland, 
U. Penn = University of Pennsylvania School of Medicine, Yonsei = Yonsei University,  
(NTBRD) = Novel TB regimen development, Source: Global Alliance for TB Drug Development .  
June 2011 
Table 1. TB Alliance Portfolio for TB drug development 
4. TB vaccines and immunizations 
Vaccines work by stimulating the immune system to retain a memory of particular 
molecules from a microbe that will trigger a rapid immune response if the microbe is 
encountered later. The best candidates for vaccines are those that trigger the strongest 
response from the immune system. The existing Bacille Calmette Guerin (BCG) vaccine, 
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which came into the market in 1921, has limited effectiveness in protecting people from TB. 
BCG is based on a live but attenuated strain of Mycobacterium bovis, which is the species 
that causes TB in cattle but can also infect humans. It is given at birth throughout the 
developing world but the problem is that BCG is not very effective - a fact made obvious 
when you consider that about 2 million people a year still die from TB. It is also reported 
that the BCG vaccine, which is used to prevent childhood TB, may not be safe for children 
living with HIV. 
The development of a vaccine from a pool of potential candidates through clinical trials to 
delivery in a healthcare system is a costly and time-consuming process with a very high 
failure rate along the way. However, this problem not withstanding, a number of groups 
from around the world are collaborating in major partnerships, on vaccine development 
where two main vaccine strategies are being pursued: (1) a pre-infection vaccine delivered 
early in life improved from the current BCG vaccine and (2) a post-exposure vaccine that 
would invoke immunity to clinical disease after infection. With these stragies in mind, a 
number of products has reached various phases of clinical trials. 
Researchers in the TB-VAC project will select vaccines for TB that work in adults and are 
suitable for use in resource-poor settings and are safe for HIV-infected individuals. 
MUVAPRED (Mucosal Vaccines against Poverty Related Diseases) is aimed at stimulating 
local immunity to neutralise M. tuberculosis where the organism enters the body in the 
lungs. The focus is on developing vaccines that can be administered orally or as a nasal 
spray thus avoiding the risks involved in using needles.The momentum to develop a new 
and more effective vaccine is gathering pace and although there is still much work to be 
done, there is genuine optimism that a new effective vaccine can be delivered in the next ten 
years. 
4.1 New tuberculosis vaccines in pipeline 
TB vaccines under development are designed to work in one or several of the following 
ways: (1) Prevent infection; (2) Prevent primary disease; (3) Prevent latent infection;  
(4) Prevent reactivation of latent infection or (5) Shorten the course and improve the 
response to chemotherapy. 
4.1.1 Tuberculosis Vaccine Pipeline - 2010 
In the 2010 Tuberculosis Vaccine Pipeline, tuberculosis vaccine candidates are presented in 
three categories: 
a. Candidates Tested in Clinical Trials (Section I): TB vaccine candidates that were in 
clinical studies in 2010. Certain candidates that have been in clinical studies but are not 
currently in clinical trials are listed as ‘completed.’ 
b. Candidates in Preclinical Studies & GMP-2010 (Section II): TB vaccine candidates that as 
of 2010 were not yet in clinical trials, but have been manufactured under good 
manufacturing practice (GMP) for clinical use and have undergone some preclinical 
testing that meets regulatory standards. 
c. Next Generation Candidates-2010 (Section III): TB vaccine candidates that are in the 
research and development stage with some preclinical testing performed to show that 
they may confer protection.  
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Type of 
vaccine  
Products  Product description  Sponsor  Indication Status as of 
2010  
  
Recombinant  
Live  
 
VPM 1002 
 
rBCG Prague strain 
expressing listeriolysin 
and 
carries a urease deletion 
mutation 
Max Planck, 
Vakzine 
Projekt 
Management 
GmbH, 
Prime rBCG, 
Booster 
TBVI Phase Ib 
 
 
rBCG30 
rBCG Tice strain 
expressing 30 kDa Mtb 
antigen 85B; phase I 
completed in U.S.. 
UCLA, NIH, 
NIAID, Aeras
 
 Prime Phase I 
[completed] 
 
AERAS‐422 
 
Recombinant BCG 
expressing mutated PfoA 
and overexpressing 
antigens 85A, 85B, and 
Rv3407 
Aeras Prime  
Phase I 
Viral Vectored Oxford 
MVA85A / 
AERAS‐485 
 
Modified vaccinia Ankara 
vector expressing 
Mtb antigen 85A 
 
Oxford 
Emergent 
Tubcerulosis 
Consortium 
(OETC), 
Aeras 
Boost, Post-
infection, 
Immuno-
therapy 
Phase IIb 
AERAS‐402/ 
Crucell 
Ad35 
 
Replication‐deficient 
adenovirus 35 vector 
expressing Mtb antigens 
85A, 85B, TB10.4 
Crucell, Aeras  Boost Phase IIb 
 
AdAg85A 
 
Replication‐deficient 
adenovirus 5 vector 
expressing Mtb antigen 
85A 
 
McMaster 
University in 
Canada. 
Prime , 
Boost 
 
Phase I 
Recombinant 
Protein 
 
M72 + AS01 
(GSK M72) 
 
Recombinant protein 
composed of a fusion of 
Mtb antigens Rv1196 and 
Rv0125 & adjuvant 
AS01 
GSK, Aeras, 
othrers  
Boost, 
Post- 
Infection 
Phase II  
 
Hybrid‐I+ 
IC31 (SSI 
Hybrid 1 
(H1)) 
 
Adjuvanted Recombinant 
protein (Ag85B plus ESAT 
6) fusion molecule with 
adjuvant (IC31). 
recombinant protein 
composed of  
Mtb antigens 85B  
and ESAT‐6 
Statens Serum 
Institute (SSI),
TBVI, 
EDCTP, 
Intercell 
Prime, 
Boost, 
Post-
infection 
Phase I/II  
 
Hybrid‐I+ 
CAF01 
 
Adjuvanted recombinant 
protein composed of 
Mtb antigens 85B and 
ESAT6 
SSI Prime, 
Boost, 
Post-
inection. 
Phase I – 
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Type of 
vaccine  
Products  Product description  Sponsor  Indication Status as of 
2010  
HyVac 
4/AERAS 
404, 
+IC31 
Recombi-nant 
protein 
(Ag85B plus 
TB10.4) 
fusion 
molecule with 
adjuvant 
(IC31).  
 
 
Adjuvanted recombinant 
protein composed of 
a fusion of Mtb antigens 
85B and TB10.4 
 
SSI, Sanofi 
Pasteur, 
Aeras, 
Intercell 
  
Boosting 
vaccine for 
prevention 
of new TB in 
BCG 
vaccinated 
infants. 
Phase I  
 
Whole Cell, 
Inactivated or 
Disrupted 
 
M. vaccae 
(Investiga-
tional heat-
killed 
preparation 
derived from 
rough variant 
of an 
environmental 
isolate).  
 
Inactivated whole cell non 
TB mycobacterium; 
phase III in BCG primed 
HIV+ population 
completed; reformulation 
pending 
 
NIH, 
Immodulon 
(with Aeras). 
Booster to 
BCG, for 
HIV 
infected. 
Post-
infection, 
Immuno-
therapy 
Phase III 
[completed] 
 
Mw [M. 
indicus pranii
(MIP)] 
 
 
Whole cell saprophytic 
non TB mycobacterium 
 
Department 
of 
Biotechnology
(Ministry of 
Science & 
Techno-logy, 
Govern-ment 
of 
India), M/s. 
Cadila 
Pharma-
ceuticals Ltd. 
 
Immuno-
therapy 
Phase III  
 
RUTI 
 
Fragmented Mtb cells 
Based on detoxified 
cellular fragments of M. 
tuberculosis. 
Archivel 
Farma, S.I. 
Being 
develop-ed 
by Germans 
Trias i Pujol 
Health 
Science 
Research 
Targets 
subjects 
with latent 
new TB 
infection 
(LTBI). 
 Phase II  
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Type of 
vaccine  
Products  Product description  Sponsor  Indication Status as of 
2010  
 
M. 
smegmatisa 
Whole cell extract; phase I 
completed in China – 
 
- Boost, 
Post-
infection, 
Immuno-
therapy 
Phase I 
[completed] 
 
Table 2. Candidates Tested in Clinical Trials (SECTION I) 
The vaccine candidates are further subdivided into specific vaccine types: (1) Recombinant 
Live (2) Viral Vectored (3) Recombinant Protein or (4) Other. A brief description is also 
provided. The Table lists vaccines intended to be used as a Prime (P) or Booster (B) vaccine, 
as a Post-infection vaccine (PI) or in immunotherapy (IT). The information contained here 
was provided and updated by the vaccine developers unless otherwise indicated. In cases 
where an update regarding a previously listed vaccine candidate was not received in 2010, 
the 2009 listing was retained. 
 
Type of 
vaccine  
Products  Product description   Sponsor  Indication 
Recombinant 
Live 
 
Mtb  
[ΔlysA ΔpanCD 
ΔsecA2] 
 
Non replicating, Mtb strain 
auxotrophic for 
lysine and pantothenate; 
attenuated for secA2 
 
Albert Einstein 
College of 
Medicine 
 
Prime  
MTBVAC [ΔphoP, 
Δfad 
D26] 
 
Live vaccine based on attenuation 
of Mtb by 
stable inactivation by deletion of 
phoP and fad 
D26 genes 
University of 
Zaragoza, 
Institute Pasteur, 
BIOFABRI, 
TBVI 
 
Prime 
Recombinant 
Protein  
HBHA Naturally methylated 21 kDa 
purified protein 
from M.bovis BCG 
 
Institute Pasteur 
of Lille, 
 INSERM, TBVI  
 
Prime, 
Boost, 
Post- 
infection, 
Immuno-
therapy 
Hybrid 56 + IC31 
 
 
Adjuvanted recombinant protein 
composed of 
Mtb antigens 85B, ESAT6 and 
Rv2660 
 
SSI, Aeras, 
Intercell 
Prime , 
Boost, 
Post- 
Infection. 
 Other 
 
HG85 A/B Chimeric DNA vaccines—
Ag85A/Ag85B 
Shanghai H&G 
Biotech  
 
Boost, 
Immuno-
threapy 
Spray-dried BCGb 
 
Live attenuated BCG Danish 
Strain spray-dried 
for nasal administration 
 
MEND  
 
Prime 
Table 3. Candidates in Preclinical Studies & GMP 2010 (SECTION II) 
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Type of 
vaccine  
Products  Product description   Sponsor  Indication 
 
Recombi-
nant Live 
 
 
HG856, BCG 
 
 
rBCG overexpressing chimeric 
ESAT6/Ag85A 
DNA fusion protein 
 
 
Shanghai Public 
Health Clinical 
Center 
 
 
Boost, 
Post-infection, 
Immunotherapy 
IKEPLUS M. 
smegmatis 
with ESX3 
deletion/ 
complementation
 
Live M. smegmatis with deletion 
of ESX3 
encoding locus and 
complementation with Mtb 
locus 
 
Albert Einstein 
College of 
Medicine, Aeras  
 
Boost 
paBCG 
 
BCG with reduced activity of 
anti apoptotic 
microbial enzymes including 
SodA, GlnA1, 
thioredoxin, and thioredoxin 
reductase 
Vanderbilt 
University  
 
Prime 
 
Proapoptotic 
rBCG 
 
Recombinant BCG expressing 
mutated PfoA 
and including mutations shown 
at AECOM to 
induce macrophage apoptosis 
 
Aeras, Albert 
Einstein College 
of Medicine 
Prime 
 
rBCG(mbtB)30 
 
rBCG with limited replication 
overexpressing 
the 30 kDa Mtb Antigen 85B 
 
UCLA, NIH, NIAID 
 
Prime 
rBCG T+B 
rM. smegmatis 
T+B 
 
rBCG and rM. smegmatis 
expressing multiple T 
and B epitopes of Mtb 
 
Finlay Institute, 
Universiti Sains 
Malaysia  
 
Prime, 
Boost, 
Post- 
Infection 
 
rBCG TB Malaria
 
Expresses multiple epitopes of 
Mtb fused to 
malarial epitopes and antigens 
 
Universiti Sains 
Malaysia  
 
Prime , 
Boost, 
Ppost- 
Infection 
rBCG38 
 
rBCG Tice strain overexpress the 
38 kDa 
protein 
 
Universidad 
Nacional 
Autónoma de 
México  
Prime, 
Boost 
rBCGMex38 
 
rBCG Mexico strain overexpress 
the 38 kDa 
protein 
 
Universidad 
Nacional 
Autónoma de 
Mexico  
Prime, 
Boost 
rBCG 
overexpressing 
L,D 
Transpeptidase 
 
Recombinant M. bovis BCG 
overexpressing an 
Mtb L,D Transpeptidase 
 
Johns Hopkins 
University  
 
Prime 
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Type of 
vaccine  
Products  Product description   Sponsor  Indication 
Replication 
deficient 
rBCG 
 
Recombinant BCG expressing 
PfoA and 
classical, latency, and 
resuscitation antigens 
in live, non replicating 
background 
 
Aeras  
 
Prime 
rM.microti30 
rM.microti38 
 
rM.microti strain overexpress 
the 30 or 38kDa 
protein 
 
Universidad 
Nacional 
Autónoma de 
Mexico  
 
Prime 
Streptomyces live
vector 
 
Recombinant streptomyces 
expressing multiple 
T and B epitopes from M.tb 
 
Finlay Institute, 
Institute of 
Pharmacy and Food, 
Cuba  
 
Prime, 
Boost, 
Post-infection, 
 
Recombi-
nant 
Protein 
 
ID93 in GLASE 
adjuvant 
 
Subunit fusion protein 
composed of 4 Mtb 
antigens 
 
Infectious Disease 
Research 
Institute  
 
Boost, 
Post-infection, 
Immunotherapy 
Latency fusion 
proteins 
 
Recombinant fusion proteins 
composed of 
antigens 85A85B,Rv3407, 
Rv3407,Rv1733, 
Rv2626, Rv0867,R1884,Rv2389 
 
Aeras 
 
Boost 
 30kDa Mtb Ag85B protein 
purified from 
rM. Smegmatis 
 
 
UCLA, NIH, NIAID 
 
Boost, 
Post-infection 
R32Kda 
(recombinant 
85A) 
 
Purified recombinant 85A 
protein from BCG 
 
Bhagawan Mahavir 
Medical 
Research Center, 
LEPRA Society 
Blue Peter Research 
Centre 
 
 
Boost, 
Postinection 
,Immuno-
therapy 
Viral 
Vectored 
 
Recombi-nant 
LCMV 
 
Recombinant lymphocytic 
choriomeningitis 
virus expressing Ag85A, Ag85B, 
or Ag85BESAT6 
 
University of 
Geneva 
 
Prime, Boost, 
Post-infection, 
Immunotherapy 
pND 14 vector  With tpa factor expressing esat6,
cfp10, hspx, Ag85A, Ag85B, or 
Ag85 
 
 
HEC Pakistan  
 
Prime, 
Boost, 
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Type of 
vaccine  
Products  Product description   Sponsor  Indication 
 
Other 
Ac2SGL 
Diacylated 
Sulfoglycolipid 
 
Mycobacterial lipids with 
Ac2SGL, a novel 
glycolipid antigen 
 
Institut de 
Pharmacologie et 
Biologie Structurale 
du CNRS  
 
 
Prime, 
Boosr, 
Post-infection, 
Immunotherapy 
HG856A 
 
Chimeric DNA vaccines—
ESAT6/Ag85A; 
Ag85A/Ag85B 
 
Shanghai H&G 
Biotech  
 
Boost, 
Immun-otherapy 
HG856SeV 
 
Recombinant Sendai virus 
overexpressing 
chimeric ESAT 6/Ag85A protein
 
Shanghai H&G 
Biotech  
 
Boost 
Hsp DNA 
vaccine 
 
Codon optimized heat shock 
protein from M. 
leprae, a CpG island 
 
 
Cardiff University, 
Sequella  
 
Boost 
HVJ 
Envelope/HSP65
DNA+IL12 DNA
 
Combination of DNA vaccines 
expressing 
mycobacterial heat shock 
protein 65 & IL12 
 
Osaka University  
 
Boost, 
Post- 
infection, 
Immuno-therapy 
 
Liporale BCG 
 
Live attenuated BCG Danish 
Strain in a novel 
lipid adjuvant and delivery 
system for an oral 
vaccine 
 
Immune Solutions 
Ltd.  
 
Prime, 
Boost 
Mycobacterial 
liposomes and 
proteosomes 
 
Liposomes from M. smegmatis 
and proteoliposomes 
from BCG and M. smegmatis 
 
Finlay Institute 
Universiti Sains 
Malaysia  
 
Prime, 
Boost, 
Post-inection, 
Immuno-therapy 
 
NasL3/AM85B 
conjugate 
 
Nasal vaccine with man capped 
Arabinomannan 
oligosaccharide conjugated to 
Ag85B in Eurocine L3TM 
adjuvant 
 
 
Karolinska Institute 
 
Boost 
NasL3/HtkBCG 
(BCG adjuvant) 
 
Intranasal heat killed whole 
BCG Copenhagen 
strain in Eurocine L3TM 
adjuvant 
 
Karolinska Institute 
 
Prime, 
Boost, 
Post-infection, 
Immunotherapy 
 
PS conjugate Subunit Mtb polysaccharide 
protein conjugate 
 
Albert Einstein 
College of 
Medicine  
 
Boost 
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Type of 
vaccine  
Products  Product description   Sponsor  Indication 
pUMVC6/7 DNA
 
DNA vaccine plasmid vectors 
pUMVC6 or 
pUMVC7 expressing Rv3872, 
Rv3873, Rv3874, 
Rv3875 or Rv3619 
Kuwait University 
 
Prime 
Recombinant 
B/HPIV 
 
Recombinant B/HPIV vector 
encoding fusion of 
antigens 85A85B,Rv3407, 
Rv3407, Rv1733, 
Rv2626, Rv0867, Rv1884, Rv2389
 
NIH, Aeras  
 
Boost 
TBioVax  Heat shock HspC protein 
antigen complexes  
ImmunoBiology Ltd. 
 
Boost 
TBVax 
 
T cell epitope based DNA 
prime/peptide boost 
vaccine 
 
EpiVax , Inc.  Boost, 
Post-inection 
Key: BCG – Bacille Calmette Guérin, IL – Interleukin, GMP – Good Manufacturing Practices,  
GSK – GlaxoSmithKline Biologicals, M. bovis – Mycobacterium bovis, Mtb – Mycobacterium 
tuberculosis, NIAID– National Institute of Allergy and Infectious Diseases, NIH – National Institutes of 
Health, OETC – Oxford Emergent Tuberculosis Consortium, Ltd. SSI – Statum Serum Institute,  
TBVI – Tuberculosis Vaccine Initiative, UCLA – University of California Los Angeles,  
Source: Tuberculosis Vaccine Pipeline 2010  
Table 4. Next Generation Candidates – 2010 (SECTION III) 
5. Tuberculosis diagnostics 
Despite substantial investments and progress made in expansion of the directly observed 
therapy, short course (DOTS and DOTS Plus) strategy and improved treatment completion 
rates, inadequate case detection is still a major problem in the efforts to ensure global control 
of tuberculosis. There is need for health workers to be able to quickly detect resistant forms 
of tuberculosis and also to be able to distinguish clearly between active and latent 
forms.Efforts during the past decade to consistently diagnose and treat the most infectious 
cases have not been very successful. Insufficient access to advanced diagnostic tests has 
contributed to limited performance in the effort to control tuberculosis in general and 
MDR/XDR –TB in particular. Up to now, national tuberculosis programmes in disease 
endemic countries continue to rely largely on antiquated and inaccurate methods such as 
direct smear microscopy, solid culture, chest radiography, and tuberculin skin testing. There 
is still no rapid test that can allow early detection of active tuberculosis at health clinics , the 
biggest challenge bing presented by diagnosis of smear-negative tuberculosis in adults 
infected with HIV and in children.  
To these shortcomings is added the fact that even the existing diagnostics are not used to 
their full potential because of poor access to health care and failures in health-care delivery 
systems, including poor coordination between national HIV/AIDS and tuberculosis 
programmes. There are rampant diagnostic delays, misdiagnoses, and inadequate 
implementation of existing tests leading to increased morbidity and mortality in patients, 
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leave alone allowing continued transmission of MDR/XDR strains. The shorcomings of 
present-day case detection approaches are most pronounced in countries with a high 
prevalence of HIV infection or MDR/XDR tuberculosis, or both which heralds a bleaque 
picture for the control of the disease. 
5.1 Barriers to development of new tuberculosis diagnostics 
The most important barries have been (1)market failure because industry tends to avoid 
developing and marketing products that will be mainly used for poor patients in resource-
limited countries because such products will not generate profits; and (2) health systems in 
developing countries are generally weak due to poor management, insufficient financial 
resources, inadequate human resources, and poor laboratory capacity, making them unable 
to take advantage of tuberculosis diagnostics to achieve best possible performance, and to 
introduce new advances in diagnostic technologies.  
5.2 Tuberculosis diagnostics pipeline 
Over the past decade, there has been an unprecedented level of interest and activity 
focused on the development of new tools for TB diagnosis, with agencies like the Stop TB 
Partnership's New Diagnostics Working Group (NDWG), the Foundation for Innovative 
New Diagnostics (FIND), the Global Laboratory Initiative (GLI), the World Health 
Organization (WHO) and the Special Programme for Research and Training in Tropical 
Diseases (TDR), several industry partners, non-governmental agencies, and national TB 
programs being heavily involved. The impetus has been boosted by funding agencies 
such as the Bill & Melinda Gates Foundation, the Global Fund to Fight AIDS, TB and 
Malaria (GFATM), and UNITAID that have provided the much needed resources. As a 
result of this involvement, there is now a strong pipeline of improved or new tools for TB 
diagnosis.  
Fluorescence microscopy is widely used in high income countries since it offers increased 
sensitivity, and has logistical advantages such as less technician time, but is rarely used in 
resource-limited countries. Several light-emitting diode (LED) microscopes that can be used 
in fluorescence microscopy have been developed in the past few years. They are 
inexpensive, robust, consume little electricity, are highly sensitive, and need less technician 
time than does Ziehl-Neelsen microscopy. WHO recommended that conventional 
fluorescence microscopy be replaced by LED microscopy in all settings and that LED 
microscopy be phased in as an alternative for conventional Ziehl-Neelsen microscopy in 
both high-volume and low-volume laboratories. Efforts are also underway to minimise 
diagnostic delays and to improve system efficiency by optimising the number of specimens 
that are needed and the way in which they are collected (eg, so-called same-day diagnosis, 
using two sputum smears collected on the same day).  
5.3 Limitations of the existing diagnostics pipeline 
Although promising work has either been done or is the pipeline we are yet to see a simple, 
rapid, inexpensive point-of-care test for active tuberculosis that can perform as well or better 
than conventional smear microscopy, and which can deliver results within minutes without 
sophisticated equipment or laboratory requirements. Such equipment that can be able to do 
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point-of-care diagnostic tests are necessary if we are to be able to control diseases such as 
tuberculosis that need lengthy standardised, decentralised therapy. However, with patient, 
community, and activist groups providing increased funding and resources to develop such 
tests, an ideal diagnostic system can be availed in afew years to come.  
6. Biomarkers for tuberculosis 
6.1 Importance of biomarkers 
It is an established fact that biomarkers are important tools for provision of prognostic 
information about future health status, for individual patients or cohorts in clinical trials. 
They can be used to indicate normal or pathogenic processes, or pharmacological outcomes 
of therapeutic interventions. Basing on epidemiological, therapeutic, pathophysiological, or 
other scientific evidence, biomarkers can form the basis of surrogate endpoints, which can 
serve as substitutes for clinical endpoints in clinical trials. By using this approach, it possible 
to use them in drug candidate selection during drug discovery and accelerating dose 
selection in early clinical research, as well as shortening the time to licensing of new drugs 
and vaccines. In day-to-day clinical care, biomarkers can allow stratification of individual 
patients according to outcome risks, thus easing targeted interventions that might not 
otherwise produce overall benefit. Use of biomarkers can also play a vital role in the 
advancement of basic knowledge of disease pathogenesis. 
With regard to tuberculosis research, the need for biomarkers is paramount in the areas of: 
(1) patients with active disease, to predict durable or non-relapsing treatment success; (2) 
patients with latent M. tuberculosis infection, to indicate reactivation risk and predict 
treatment success; and (3) people other than those with active disease, to indicate protection 
from tuberculosis by new vaccines. Although a number of studies have been undertaken in 
this area outstanding breakthroughs are yet to be made. 
7. Existing gaps in research on XDR TB 
In the majority of areas where XDR -TB has been identified, the actual prevalence of 
resistance to first- and second-line drugs among TB cases is unknown. The figures being 
used are maily estimates and, therefore, there is need to determine the exact global 
prevalence and incidence rates of XDR-TB.  
The risk factors for and transmission dynamics of XDR-TB in domestic and international 
settings are not completely understood and the survival rates among patients with XDR-TB 
have not been adequately analyzed. Furthermore, host/pathogen determinants of survival, 
including the effect of co-morbidities, are yet to be completely elucidated.  
In the field of diagnostics, the methods for detecting and documenting outbreaks of XDR-TB 
both domestically and internationally are not currently optimized to allow a rapid response 
and to these is added lack of effective and safe treatment regimens for XDR-TB which are 
yet to be established. Rapid, point-of-care identification of drug-sensitive and drug-resistant 
pulmonary and extrapulmonary TB among HIV-negative and HIV-positive adults and 
pediatric populations and reliable early identification of latent M. tuberculosis infection are 
not yet possible.  
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Another scientific obstacle impeding progress is that up to now we do not have a icomplete 
understanding of the biology of M tuberculosis and its nteractions with the human host. 
These knowledge gaps impede the development of biomarkers that can distinguish between 
the different forms and stages of tuberculosis especially in immunocompromised patients 
and in children. The present diagnostic tests for latent M. tuberculosis infection do not 
adequately distinguish resolved from persistent infection, and are unable to efficiently 
identify individuals who are at highest risk of reactivation. 
Furthermore, studies into the predictive value of Interferon-γ–release assays (IGRAs) have 
only shown modest outcomes, and several studies show similarly low rates of progression 
in people with positive tuberculin skin test and IGRA results. Other gray areas are in the 
area of diagnosis of smear-negative tuberculosis in children and HIV-infected individuals, 
as well as inablity to carry out rapid and accurate identification of resistance to second-line 
antituberculosis drugs. Although molecular markers have been identified and can be used 
as rapid and accurate tests for isoniazid and rifampicin resistance, testing for the resistance 
that characterises extensively drug-resistant tuberculosis is still a problem. Well-validated 
surrogate markers to rapidly assess clinical efficacy of new chemotherapeutic agents and 
regimens against XDR-TB are yet to be put in place although a lot of research is on going.  
With regard to treatment of MDR/XDR-TB, effective treatments specifically designed for 
active or latent MDR/XDR-TB infection have not been established. Coupled with this is the 
fact that the complete pharmacology of existing and new TB drugs, including interactions 
with antiretroviral medications commonly used among high-risk populations, has not been 
adequately assessed.  
Furthermore, there are still gaps in the areas of characterisation of the efficacy, safety and 
pharmacology of TB chemotherapeutics in special populations such as children, injection 
drug users and persons with HIV/AIDS, among other situations. 
Further still, the quality of currently available services and treatments for MDR/XDR-TB 
patients has not been monitored or evaluated sufficiently and safe and more effective 
treatment regimens and appropriate follow-up procedures for managing contacts of XDR-
TB patients are yet to be properly established. Another area of concern has been the fact 
that, despite M. tuberculosis having been known for a long time, there have been gaps in the 
knowledge of its characteristics with regard to growth, physiology, biochemistry, genetics, 
and molecular biology although this situation is now being addressed, as more and more 
research has been undertaken in these areas. 
Finally, there is need to have in place, a comprehensive and up-to-date estimate of the costs 
of diagnosing, treating, and managing XDR-TB if cost-effective strategies to prevent XDR-TB 
are to be established.  
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